 |
Imiglucerase review
|
Imiglucerase is an enzyme that is used to replace that lost by people suffering from Gaucher’s disease. Imiglucerase relieves the symptoms associated with this illness and prevents the buildup of complications due to this disease. Genzyme Corporation sells Imiglucerase for injection under the brand name Cerezyme, a sterile, non-pyrogenic, white to off-white lyophilized injectible product.
Cerezyme is prescribed as a long-term enzyme replacement therapy for both children and adult patients who are suffering from Type 1 Gaucher disease. Treatment with imiglucerase injection is meant for such patients who are suffering from any or more of the following: anemia, bone disease, thrombocytopenia, and hepatomegaly (abnormal enlargement of the liver) or splenomegaly (abnormal enlargement of the spleen).
Imiglucerase is injected through a patient’s vein during a one- to two-hour period. The dosage required for each person varies. It depends on the patient’s state of health as well as his reaction to this medication. It may be as often as three times every week, or as seldom as twice every month. The patient must follow his doctor’s advice on dosing strictly.
A person undergoing imiglucerase treatment may experience headache, nausea, dizziness, and upset stomach. Others also experienced pruritus (severe skin itching), urticaria (or hives), cyanosis (bluish skin), hypotension (extremely low blood pressure), abscess (open wound or sore) at the site of injection, and angioedema. If these side effects persist or worsen, it is best to seek the doctor’s advice.
It is unlikely for anyone to have serious allergic reaction to imiglucerase. If such occurs, the patient must immediately inform his physician. Examples of allergic reactions that warrant immediate action include chest pain, dyspnea (breathing difficulty), diarrhea, rash, itching, swelling, flushing, and extreme dizziness. Other forms of reaction should also be relayed to the patient’s doctor immediately.
To ensure the patient’s safety while undergoing imiglucerase treatment, the patient must inform his doctor of other illnesses he has or he suspects he has. If the patient is allergic to specific drugs, he should inform his doctor early on. The doctor also needs to know if his patient has an allergic reaction to imiglucerase, alglucerase (Ceredase), or have antibodies to either medication. The patient must also apprise his doctor if he is taking any over-the-counter or prescription drug. If he has breathing problems or pulmonary hypertension, he must inform his doctor as well.
Imiglucerase may cause dizziness, and so people who engage in activities that involve mental and physical sharpness such as driving, machinery handling, and others, should be wary while using this medication.
It is ideal to avoid alcoholic beverages while undergoing imiglucerase treatment. Pregnant women should also inform their doctor before using imiglucerase. While there is no report yet of imiglucerase being in breast milk, the patient must inform her doctor before breast-feeding.
As of date, no contraindications have been reported to the use of Cerezyme (imiglucerase for injection). Cerezyme treatment must be thoroughly re-evaluated if the patient experiences hypersensitivity to the medication.
As with other medications, the patient should not begin or stop taking imiglucerase without his doctor’s approval.
• Molecular formula of imiglucerase is C2532H3854N672O711S16
• Chemical IUPAC Name is Human Beta-glucocerebrosidase
• Molecular weight is 55597.4 g/mol
Generic name: Alglucerase
Brand name(s): Ceredase
Review published on: 26 August 2009
 Your Imiglucerase review
Other popular drugs: Ergocalciferol ::
Livial ::
Ailural
|
Home
E-Mail
Site Map
http://www.medical-look.com
FORUM 
Buy Imiglucerase
